(JNJ) Johnson & Johnson Company Overview

What does Johnson & Johnson do today?

Johnson & Johnson is no longer the diversified consumer-and-healthcare conglomerate many readers remember from older case studies. After the Kenvue consumer-health separation, the current company is a focused healthcare innovation business built around Innovative Medicine and MedTech. The official company site describes these two areas as medicines and therapies, where Johnson & Johnson targets oncology, immunology, neuroscience and cardiopulmonary disease, and medical devices and technology, where it focuses on cardiovascular, orthopaedics, surgery and vision care across the Johnson & Johnson enterprise.

How should researchers classify the company?

For MBA and investor analysis, Johnson & Johnson should be treated as a regulated, research-intensive healthcare company with two different economic engines. Innovative Medicine has drug-discovery, patent, clinical-trial, reimbursement and exclusivity risk. MedTech has procedure-volume, surgeon adoption, hospital purchasing, device innovation and supply-chain risk. The common thread is not consumer brand marketing; it is clinical credibility, regulatory execution, global distribution and reinvestment into science.

How does Johnson & Johnson make money?

Johnson & Johnson makes money primarily by selling prescription medicines and medical technologies. In Innovative Medicine, the company earns revenue from branded drugs and biologics such as DARZALEX, TREMFYA, STELARA, SPRAVATO, CARVYKTI and OPSUMIT/OPSYNVI. In MedTech, it sells cardiovascular devices, surgical products, orthopaedic implants and vision products. The 2025 Form 10-K states that medicines are distributed to retailers, wholesalers, distributors, hospitals and healthcare professionals, while MedTech products are distributed to wholesalers, hospitals and retailers and used mainly by physicians, nurses, hospitals, eye-care professionals and clinics in the company’s annual report.

Which segment carries the profit pool?

The strongest profit pool is Innovative Medicine. In FY2025, Innovative Medicine generated $60.4B of sales and $22.3B of segment income before tax, equal to a 36.9% segment income-before-tax margin. MedTech generated $33.8B of sales and $4.1B of segment income before tax, equal to a 12.2% margin. The contrast matters because a dollar of drug revenue and a dollar of device revenue do not carry the same reinvestment, patent, pricing or operating-risk profile.

Which products and segments matter most?

Johnson & Johnson’s revenue mix is concentrated enough to analyze, but broad enough that no single product defines the whole company. The core issue is replacement: oncology and newer immunology, neuroscience and cardiovascular products need to offset erosion in older products such as STELARA, IMBRUVICA, XARELTO and other products facing competitive or reimbursement pressure.

What is the FY2025 segment mix?

The segment split shows why a traditional “healthcare conglomerate” description is incomplete. Innovative Medicine is the larger and more profitable segment, but its moat has to be renewed through R&D, labels, indications and acquisitions. MedTech adds diversification and procedure-based growth, yet it is also being reshaped by the planned orthopaedics separation.

Which products are the current growth engines?

What does Johnson & Johnson’s latest quarter show?

The freshest official reporting package as of this article is Q1 2026. Johnson & Johnson reported first-quarter 2026 sales of $24.1B, up 9.9% as reported, with operational growth of 6.4% and adjusted operational growth of 5.3%. The company also reported diluted EPS of $2.14, adjusted diluted EPS of $2.70 and raised its 2026 outlook to estimated reported sales of $100.8B at the midpoint and adjusted EPS of $11.55 at the midpoint in the Q1 2026 earnings release.

Which Q1 2026 numbers are most useful?

How did segments perform in Q1 2026?

In the Q1 2026 Form 10-Q, Innovative Medicine sales rose 11.2% to $15.4B and MedTech sales rose 7.7% to $8.6B. Management disclosed that STELARA’s decline from biosimilar competition reduced worldwide operational sales by approximately 5.4%, making the quarter stronger than the headline would appear because the remaining portfolio had to outgrow a large product cliff in the Q1 2026 Form 10-Q.

How did Johnson & Johnson become strategically important?

Johnson & Johnson’s strategic history is not just a long corporate timeline. The relevant pattern is a repeated move into clinically important, trust-sensitive healthcare categories: sterile surgery, pharmaceuticals, sutures, orthopaedics, biologics, cardiovascular devices, consumer separation and now sharper portfolio focus. The company’s official heritage timeline traces the model back to sterile surgical supplies, mass-produced antiseptic products and the 1943 Credo in the company timeline.

Which turning points still shape the business?

1. 1886
   Johnson & Johnson is founded and begins scaling sterile surgical supplies. This origin still explains the company’s credibility in medically sensitive categories.
2. 1943
   Our Credo is written before the company becomes publicly traded. It remains a governance and culture reference point, especially in a trust-heavy sector.
3. 1961
   The Janssen Pharmaceutica acquisition deepens the pharmaceutical platform that later becomes central to Innovative Medicine.
4. 1998
   The DePuy acquisition expands orthopaedics, creating a large MedTech franchise that is now being prepared for separation.
5. 2023
   The Kenvue separation removes most consumer-health exposure and clarifies Johnson & Johnson as an Innovative Medicine and MedTech company.
6. 2025
   Intra-Cellular and Halda acquisitions add neuroscience and oncology pipeline assets; the orthopaedics separation plan accelerates portfolio focus.

How do patents, pipeline, and MedTech procedure volume shape the model?

Healthcare analysis of Johnson & Johnson should start with three sector-specific forces. First, patent and exclusivity periods create temporary profit pools but also cliffs. Second, clinical and regulatory execution determines whether the next product cycle arrives in time. Third, MedTech revenue depends on procedure growth, hospital budgets, surgeon adoption and product performance, not only unit price.

Where is the Q1 2026 operating momentum?

What is the patent-cliff trade-off?

The STELARA example is the clearest current case. In Q1 2026, STELARA sales fell to $656M from $1.625B a year earlier, a 59.7% reported decline, and the company expects continued global biosimilar launches to negatively affect STELARA sales. At the same time, TREMFYA grew 68.3% to $1.608B in Q1 2026. That does not erase the cliff, but it shows the replacement logic investors should test.

How does the orthopaedics separation affect the sector story?

In October 2025, Johnson & Johnson announced its intent to separate its Orthopaedics business, with DePuy Synthes expected to become a standalone orthopaedics-focused company. The company said the planned separation would sharpen Johnson & Johnson’s focus on higher-growth and higher-margin markets, while the orthopaedics business would address a $50B-plus global market and had generated approximately $9.2B of FY2024 sales in the orthopaedics separation announcement.

What gives Johnson & Johnson a competitive advantage?

Johnson & Johnson’s competitive advantage is not one simple moat. It is a portfolio of advantages: scientific depth, regulatory experience, global clinical relationships, manufacturing quality, brand trust in healthcare, balance-sheet capacity and a record of acquiring external innovation. Those advantages are powerful, but not absolute. Patents expire, hospitals negotiate, payors pressure prices, and device rivals can win share with better technology.

Who pressures the business?

Where does Johnson & Johnson sit strategically?

How financially strong is Johnson & Johnson?

Johnson & Johnson remains financially strong, but the balance sheet is no longer a story of excess cash alone. FY2025 acquisitions, including Intra-Cellular, increased debt and intangible assets, while operating cash flow, dividends and buybacks remained large. For DCF analysis, the key issue is whether the company can maintain high cash conversion while absorbing patent cliffs, litigation, pricing pressure and acquisition integration.

What do margins and cash flow indicate?

How does capital allocation affect the story?

Who owns Johnson & Johnson stock, and why does governance matter?

Johnson & Johnson has a dispersed, one-share-one-vote ownership structure rather than founder or family voting control. The 2026 proxy statement states that common stock is the only class of shares outstanding and that each share of common stock was entitled to one vote at the 2026 Annual Meeting. On the February 24, 2026 record date, 2,408,613,219 shares were outstanding in the 2026 proxy statement.

Which shareholders matter most?

What governance signals should investors read?

The proxy describes 12 director nominees for the 2026 Annual Meeting. It also states that all directors other than the Chairman and CEO are independent, that independent directors appoint a Lead Independent Director annually, and that major committees other than the Finance Committee are composed only of independent directors. That matters because Johnson & Johnson is not controlled by insiders; portfolio choices such as acquisitions, litigation strategy, dividends and separations are scrutinized through a board-and-institutional-investor governance model.

What risks and opportunities could change Johnson & Johnson’s outlook?

Johnson & Johnson’s main opportunities come from successful portfolio replacement: oncology growth, TREMFYA expansion, neuroscience assets from Intra-Cellular, cardiovascular MedTech, procedure growth and the orthopaedics separation. Its main risks are the mirror image: patent and biosimilar erosion, failed clinical execution, pricing pressure, litigation, device competition, tariffs, supply-chain disruption and integration risk.

Which filing-sourced risks are most material?

The annual report’s risk discussion highlights product-development uncertainty, patent challenges, generic and biosimilar competition, product safety and efficacy concerns, litigation, government scrutiny, healthcare-pricing pressure, reimbursement changes, strategic-initiative execution, international operations, inflation, rates, currency, tariffs and supply-chain disruption. Those are not generic warnings for Johnson & Johnson; they map directly to current events in STELARA, talc litigation, MedTech tariffs, orthopaedics separation and the need to integrate acquired pipeline assets.

Why does Johnson & Johnson matter for valuation?

Johnson & Johnson is a useful DCF case because it combines defensive healthcare demand with very real renewal risk. A simple revenue multiple misses the economic split between high-margin Innovative Medicine and lower-margin MedTech, and a simple dividend model misses the scale of R&D, acquisitions and legal uncertainty. The right valuation lens separates durable cash generation from the reinvestment required to protect it.

Which DCF drivers matter most?

How should a student model the business?

A practical model would separate Innovative Medicine and MedTech revenue, apply different margin assumptions, include R&D as a recurring operating cost, model capex separately from acquisition spending, and stress-test patent erosion. The terminal value should not assume that current medicine margins persist automatically; it should require evidence that the pipeline, labels, acquisitions and MedTech growth platforms can keep replacing mature assets.

• Use sales growth assumptions that distinguish reported growth, operational growth, currency and acquisition contribution.
• Model STELARA and other mature-product erosion explicitly rather than smoothing it into one blended growth rate.
• Treat dividends and buybacks as capital allocation outputs, not drivers of intrinsic value by themselves.
• Stress-test gross margin, R&D intensity, litigation costs, restructuring costs and debt interest expense.
• Reflect the planned orthopaedics separation by considering the possible mix shift toward higher-growth Innovative Medicine, Cardiovascular, Surgery and Vision platforms.

What is the key takeaway from Johnson & Johnson analysis?

Johnson & Johnson is important because it sits at the intersection of scale, science, clinical trust and capital allocation. The company has one of the broadest healthcare platforms in the public market, but its current investment story is more focused and more complex than the old consumer-health conglomerate narrative. It is now a two-segment healthcare innovation company with a large Innovative Medicine profit pool, a reshaping MedTech portfolio, meaningful acquisition dependence and active exposure to patent cliffs, reimbursement and litigation.

What should researchers monitor next?

The highest-value watch items are Q2 2026 sales momentum, STELARA biosimilar impact, TREMFYA and DARZALEX growth, CAPLYTA integration, cardiovascular procedure growth, MedTech margin recovery, orthopaedics separation milestones, operating cash flow after working-capital swings, debt reduction or refinancing, and any update on major litigation reserves. These items determine whether Johnson & Johnson’s current portfolio focus becomes a stronger long-term cash-flow story or simply a more concentrated exposure to healthcare innovation risk.